drugset / Trial / NCT01473732
Mechanisms and Treatment of Chronic Allograft Injury (CAI) Due to Calcineurin Inhibitor (CNI) Toxicity
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to find out how well the current drug regimen (including low Prograf dose and Myfortic, which is usually recommended to prevent any further deterioration in the kidney function) works and how safe it is when compared to a combination of Zortress and Myfortic in patients with chronic kidney injury associated with Prograf or Neoral use.
Timeline
- Start
- 2012-03
- Primary completion
- 2012-08
- Completion
- 2012-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 1.5 mg | — |
| Comparator | Tacrolimus | Small molecule | — | — |
| Background | mycophenolic acid | Small molecule | 360 mg | — |
| Background | mycophenolic acid | Small molecule | 720 mg | — |